A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease.

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the
efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD.
Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab
or placebo every 4 weeks (Q4W) for 100 weeks. The final efficacy and safety assessment will
be performed 52 weeks after the last crenezumab dose. Participants will then have the option
to enter the Open Label Extension (OLE) study if eligible. Participants who do not enter the
OLE study will have additional follow-up visits at 16 and 52 weeks after the last dose,
primarily for safety and also for limited efficacy assessments.